HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

She works as both a clinician and a dermatological researcher, specializing in skin cancer prevention and ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed additional data on Saturday from the Phase 3 PANOVA ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Bodybuilder Sadik Hadzovic’s arm day isn’t flashy, but it’ll light your biceps and triceps on fire. Hadzovic just dropped his ...

“Dr. Pimple Popper: Breaking Out” features the most famous dermatological surgeon in the world, Dr. Sandra Lee. Check out ...

Novocure (Nasdaq:NVCR) today announced positive results from the Phase 3 PANOVA-3 trial of its tumor-treating fields (TTFields) therapy.

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Syncromune, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination immunotherapy optimized for solid tumor cancers, today announced ...